Please find enclosed herewith unaudited standalone financial results for the Quarter and half Yearly ended on September 30th, 2025.
Price
▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.
On the reaction day the stock moved 1.8 pts less than Nifty Microcap 250 and 1.5 pts less than its Pharmaceuticals & Biotechnology peers, over the same two closes: a difference in percentage points, not a measure of what the filing did.
Minute windows have no benchmark: there is no intraday index history to compare against.
Genomic Valley Biotech, a floriculture company, reported Q2 FY26 revenue from operations of Rs 9.00 lakh, flat versus Q1 FY26 but down sharply from Rs 20.50 lakh in Q2 FY25. Half-yearly revenue fell about 50% to Rs 18.00 lakh from Rs 36.03 lakh a year ago. Profit after tax for Q2 FY26 collapsed to just Rs 33,049 (EPS Rs 0.01) versus Rs 14.76 lakh (EPS Rs 0.48) in the year-ago quarter, while H1 FY26 PAT dropped to Rs 2.80 lakh from Rs 27.51 lakh. Operating cash flow turned negative at Rs -3.81 lakh in H1 FY26 against a positive Rs 42.85 lakh last year, and cash on hand is very thin at just Rs 55,506. Trade receivables remain very high at Rs 2.21 crore, far exceeding current revenue levels. The statutory auditor issued an unqualified limited review report.
Sharp revenue decline, drastically lower profits, and negative operating cash flow point to serious business slowdown and possible stress on the small company, though the clean audit review limits immediate governance concerns. Stock may remain weak on poor operating performance.